Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Research

Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States, 2020

Kathryn WingleeComments to Author , Andrew N. Hill, Adam J. Langer, and Julie L. Self
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 4

Comparison of National Tuberculosis Surveillance System (NTSS) case counts and IQVIA projected patient counts for isoniazid or pyrazinamide prescriptions, United States, 2020. A, B) Projected patient counts for isoniazid (A) and pyrazinamide (B). Horizontal axis of each plot shows NTSS patient counts aggregated by treatment start date (month), removing patients who had reported resistance. Each point represents a month in 2020. The Pearson correlation coefficient (r) is shown in lower righthand corner of each plot. C, D) A linear model fit to the 2006–2019 data (Figure 1) with quarter as a covariate to predict 2020 IQVIA projected patient counts for isoniazid (C) or pyrazinamide (D). Black line indicates actual data; gray line indicates expected IQVIA counts with 95% prediction intervals. Note vertical axes are different because of different scales for isoniazid and pyrazinamide in the IQVIA dataset. NTSS, National Tuberculosis Surveillance System.

Figure 4. Comparison of National Tuberculosis Surveillance System (NTSS) case counts and IQVIA projected patient counts for isoniazid or pyrazinamide prescriptions, United States, 2020. A, B) Projected patient counts for isoniazid (A) and pyrazinamide (B). Horizontal axis of each plot shows NTSS patient counts aggregated by treatment start date (month), removing patients who had reported resistance. Each point represents a month in 2020. The Pearson correlation coefficient (r) is shown in lower righthand corner of each plot. C, D) A linear model fit to the 2006–2019 data (Figure 1) with quarter as a covariate to predict 2020 IQVIA projected patient counts for isoniazid (C) or pyrazinamide (D). Black line indicates actual data; gray line indicates expected IQVIA counts with 95% prediction intervals. Note vertical axes are different because of different scales for isoniazid and pyrazinamide in the IQVIA dataset. NTSS, National Tuberculosis Surveillance System.

Main Article

Page created: January 31, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external